GRAIL Inc.

26.85
-1.73 (-6.05%)
At close: Mar 28, 2025, 3:59 PM
26.75
-0.37%
After-hours: Mar 28, 2025, 06:45 PM EDT

Company Description

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection.

The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.

It is also developing minimal residual disease and other post-diagnostic tests.

The company was incorporated in 2015 and is based in Menlo Park, California.

GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.

GRAIL Inc.
GRAIL Inc. logo
Country United States
IPO Date Jun 12, 2024
Industry Medical - Diagnostics & Research
Sector Healthcare
Employees 1,000
CEO Robert P. Ragusa

Contact Details

Address:
1525 O’Brien Drive
Menlo Park, California
United States
Website https://grail.com

Stock Details

Ticker Symbol GRAL
Exchange NASDAQ
Fiscal Year n/a
Reporting Currency USD
CIK Code 0001699031
CUSIP Number 384747101
ISIN Number US3847471014
Employer ID 86-3673636
SIC Code 8071

Key Executives

Name Position
Robert P. Ragusa Chief Executive Officer & Director
Aaron Freidin Chief Financial Officer
Abram Barth J.D., M.P.H. General Counsel
Alison Highlander Senior Vice President of Human Resources & Head of People Team
Dr. Joshua J. Ofman M.D., M.S.H.S President
Dr. Satnam Alag Ph.D. Senior Vice President of Software Engineering & Chief Security Officer
Paul Ciccolella Senior Vice President of Research, Development & Operations
Rodger Currie J.D. Senior Vice President of Government Affairs
Sir Harpal S. Kumar M.A., M.B.A., MA, MBA, MEng President of International Business & BioPharma
Trish Rowland Vice President of Corporate Communications

Latest SEC Filings

Date Type Title
Mar 12, 2025 4 Filing
Mar 12, 2025 4 Filing
Mar 12, 2025 4 Filing
Mar 06, 2025 4 Filing
Mar 06, 2025 4 Filing
Mar 06, 2025 4 Filing
Mar 05, 2025 S-8 Filing
Mar 05, 2025 10-K Annual Report
Mar 03, 2025 144 Filing
Mar 03, 2025 144 Filing